Immune Checkpoint Inhibitor in Addition to Transurethral Resection of Bladder Cancer (TUBRT) and Radiation Therapy in Patients With cT2-4aN0M0 Bladder Cancer: a Mono-centre Clinical Study
Overview
- Phase
- Phase 2
- Intervention
- Tislelizumab Injection
- Conditions
- Urinary Bladder Neoplasms
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
- Enrollment
- 65
- Locations
- 1
- Primary Endpoint
- Bladder preservation rate within 1 year, %
- Status
- Not yet recruiting
- Last Updated
- 3 years ago
Overview
Brief Summary
Nowadays, Immune Checkpoint Inhibitor (ICI) has become one of the new drugs for the treatment of advanced uroepithelial carcinoma. The Food and Drug Administration (FDA) approved ICI for bladder cancer (BC) patients who cannot tolerate cisplatin chemotherapy and whose tumors express programmed cell death protein ligand-1 (PD-L1). However, the efficacy of ICI in bladder preservation therapy for muscular invasive bladder cancer (MIBC) is unknown.
With the progressive clinical confirmation of the efficacy of immunotherapy, ICI has moved from second-line to first-line treatment in the indication of advanced unresectable BC. It even has been used in the neoadjuvant and postoperative adjuvant therapy for MIBC and non-muscle invasive bladder cancer (NMIBC) where Bacillus Calmette-Guérin (BCG) therapy has failed. Available studies have shown that neoadjuvant immunotherapy can achieve a pathological complete response (pCR) of 31%-42% for MIBC, regardless of using a single drug or combination, which is higher than that of neoadjuvant chemotherapy, and the incidence of side effects associated with neoadjuvant immunotherapy is lower than that of neoadjuvant chemotherapy, providing an effective treatment option for cisplatin-intolerant patients.
Studies have shown that radiotherapy leads to immunogenic cell death, which results in the release and presentation of tumor antigens and directs the recruitment and activation of T cells. It also induces increased expression of PD-L1 in tumor cells, which in turn improves the efficacy of immunotherapy. Thus ICI combined with radiotherapy has a synergistic antitumor effect and does not produce serious toxic side effects similar to those associated with chemotherapeutic agents.
This study proposes a novel neoadjuvant immunotherapy-based integrated bladder preservation therapy (neoadjuvant immunotherapy + TURBT + postoperative adjuvant radiotherapy combined with immunotherapy) and investigates the effectiveness and safety of this strategy in bladder preservation treatment strategy.
Detailed Description
This study aims to investigate the efficacy and safety of a comprehensive immunotherapy-based bladder preservation treatment strategy (neoadjuvant immunotherapy + TURBT + adjuvant radiation therapy (RT) combined with immunotherapy) by implementing a prospective, single-arm, single-center, open clinical trial. It aims to: 1) assess pCR (pathological complete remission rate) and pathological stage reduction rate of patients with MIBC after neoadjuvant immunotherapy. 2) assess relative risk factors that have an impact on pathological stage reduction rate and pCR. 3) assess bladder preservation rate of MIBC patients after the immunotherapy-based integrated bladder preservation therapy. 4) assess tumor recurrence-free survival, progression-free survival, and tumor-specific and overall survival rates after treatment. 5) To assess the safety of this treatment. 6) To collect tumor tissues from TURBT and study genetic variations as well as the expression of relevant biomarkers.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Age ≥ 18 years
- •Voluntary participation in this trial, able to provide a written version of informed consent, and able to understand and agree to comply with the requirements of this study.
- •BC patients with cT2-T4aN0M0 tumor/ lymph node/ metastasis (TNM) (AJCC 8th edition) staging based on histopathological confirmation by biopsy specimen and CT/MRI assessment.
- •ECOG performance status grade less than or equal to 1
Exclusion Criteria
- •Cancer in situ (CIS) confirmed by biopsy pathology.
- •Prior treatment with anti-PD-1, anti-PD-L1, anti-PD-L2, anti-cytotoxic T-lymphocyte-associated protein 4(CTLA)-4 antibody or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways (excluding BCG treatment).
- •Received other approved systemic anticancer therapy or systemic immunomodulators within 28 days prior to enrollment.
- •Severe chronic or active infection requiring systemic antibacterial, antifungal or antiviral therapy within 14 days prior to enrollment
- •Received herbal or proprietary Chinese medicine for cancer inhibition within 14 days prior to admission.
- •Received live vaccination within 28 days prior to admission.
- •Has need for long-term heavy use of hormones or other immunosuppressive drugs.
- •Potassium, sodium, or calcium abnormalities affecting treatment, interstitial lung disease, non-infectious pneumonia, or other uncontrolled systemic diseases, including diabetes, hypertension, or active heart disease.
- •Patients with chronic hepatitis B, hepatitis B virus carriers, or active hepatitis C.
- •Active, known or suspected autoimmune disease requiring systemic therapy.
Arms & Interventions
patients treated with immunotherapy-based bladder preservation therapy
Neoadjuvant immunotherapy + TURBT + postoperative adjuvant radiotherapy combined with immunotherapy.
Intervention: Tislelizumab Injection
patients treated with immunotherapy-based bladder preservation therapy
Neoadjuvant immunotherapy + TURBT + postoperative adjuvant radiotherapy combined with immunotherapy.
Intervention: Transurethral resection of bladder tumor
patients treated with immunotherapy-based bladder preservation therapy
Neoadjuvant immunotherapy + TURBT + postoperative adjuvant radiotherapy combined with immunotherapy.
Intervention: Adjuvant radiotherapy
Outcomes
Primary Outcomes
Bladder preservation rate within 1 year, %
Time Frame: 1 year after neoadjuvant immunotherapy (Tislelizumab Injection) started
The percentage of enrolled patients who didn't receive radical cystectomy 1 year after neoadjuvant immunotherapy (Tislelizumab Injection) started
Pathological complete response rate after neoadjuvant immunotherapy, %
Time Frame: right after TURBT and pathological examination of surgical specimen has concluded.
the percentage of enrolled patients who demonstrated pathological complete response after neoadjuvant immunotherapy, confirmed by pathological results of specimen extracted from TURBT.
Secondary Outcomes
- Overall survival time, day(from the start of neoadjuvant immunotherapy to 1) death of the patients by any cause; 2) the end of followup if patients are still alive by that time; 3) last follow up date if patients are lost, whichever comes first, assessed up to 156 weeks)
- Adverse event(from the start of neoadjuvant immunotherapy to the last followup check, assessed up to 156 weeks)